Table 4.

Conditional ORsa (95% CIs) for cutaneous SCC by seropositivity for each PyVb type and quartilesc of PyV seroreactivity at baseline among cases and matched controls (n = 306) from the Skin Cancer Prevention Study

PyV seroreactivityControlsSCC cases (n = 111)
(MFI units)(n = 195), n (%)n (%)OR (95% CI)
BK
 Seronegative7 (3.6)1 (0.9)1.00 (reference)
 Seropositive188 (96.4)110 (99.1)
 Quartile 154 (27.7)26 (23.4)1.00 (reference)
 Quartile 248 (24.6)14 (12.6)0.65 (0.31–1.37)
 Quartile 346 (23.6)32 (28.9)1.67 (0.86–3.23)
 Quartile 447 (24.1)39 (35.1)1.89 (0.96–3.73)
Ptrendd0.016
JC
 Seronegative45 (23.1)13 (11.7)1.00 (reference)
 Seropositive150 (76.9)98 (88.3)2.54 (1.23–5.25)
 Quartile 150 (25.6)18 (16.2)1.00 (reference)
 Quartile 249 (25.1)26 (23.4)1.60 (0.76–3.39)
 Quartile 351 (26.1)21 (18.9)1.10 (0.50–2.44)
 Quartile 445 (23.1)46 (41.4)3.13 (1.51–6.49)
Ptrendd0.0039
  • aORs obtained from conditional logistic regression analysis.

  • bPyV infection was determined in the baseline or earliest serum sample collected using seropositivity for the VP1 protein.

  • cControls may not be evenly distributed within quartiles due to uneven data distribution and the quartiles based upon all 229 controls.

  • dBased on the seroreactivity quartiles modeled as a continuous variable.